CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Market Closed - Nyse Other stock markets 20:00:02 13/03/2026 GMT			5-day change	1st Jan Change
155.46 ^USD	+1.83%		-10.89%	-22.07%

03-12	Locus Cell Co., Ltd. And Charles River Laboratories Sign Memorandum Of Understanding For Cell And Gene Therapy Collaboration	CI
03-10	Charles River Laboratories International, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-10-2026 10:00 AM

Transcript : Charles River Laboratories International, Inc., Q4 2025 Earnings Call, Feb 18, 2026

Published on 02/18/2026 at 03:23 pm GMT - Modified on 02/19/2026 at 07:51 pm GMT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories Fourth Quarter and Full Year 2025 Earnings Conference

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Charles River Laboratories International, Inc.

03-12	Locus Cell Co., Ltd. And Charles River Laboratories Sign Memorandum Of Understanding For Cell And Gene Therapy Collaboration	CI
03-10	Charles River Laboratories International, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-10-2026 10:00 AM
03-09	Baird Adjusts Price Target on Charles River Laboratories International to $197 From $193	MT
03-05	Therna Biosciences, Inc. Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics	CI
03-03	Charles River Laboratories International, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM
02-25	IQVIA Holdings Inc. (NYSE : IQV) entered into a definitive agreement to acquire European Discovery Services Assets from Charles River Laboratories International, Inc. (NYSE : CRL) for $155 million.	CI
02-25	GI Manager L.P. signed a definitive agreement to acquire Contract Development and Manufacturing Products and Services and Cell Solutions Businesses from Charles River Laboratories International, Inc..	CI
02-25	UBS Adjusts Price Target on Charles River Laboratories International to $175 From $170, Maintains Neutral Rating	MT
02-25	Sector Update: Health Care	MT
02-25	Charles River Laboratories to Sell Certain European Assets, Businesses; Full-Year 2026 Guidance Updated	MT
02-25	Charles River raises annual profit view as it sells underperforming assets	RE
02-25	Charles River Laboratories International, Inc. Revises Earnings Guidance for 2026	CI
02-25	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80 - $11.30	MT
02-20	Rothschild & Co Redburn Adjusts Charles River Laboratories PT to $200 From $211, Maintains Buy Rating	MT
02-20	Mizuho Securities Adjusts Charles River Laboratories Price Target to $175 From $215, Maintains Neutral Rating	MT